{
    "clinical_study": {
        "@rank": "14865", 
        "arm_group": [
            {
                "arm_group_label": "GAD-Alum (Diamyd) 20\u00b5g, Vitamin D and Ibuprofen", 
                "arm_group_type": "Active Comparator", 
                "description": "GAD-Alum (Diamyd) 20 \u00b5g given twice with one month interval\nVitamin D oral drops, 2000 IU/day, from Day 1 to Day 450\nIbuprofen, 400 mg/day, from Day 1 to Day 90"
            }, 
            {
                "arm_group_label": "GAD-Alum (Diamyd) 20\u00b5g and Vitamin D", 
                "arm_group_type": "Active Comparator", 
                "description": "GAD-Alum (Diamyd) 20 \u00b5g given twice with one month interval\nVitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
            }, 
            {
                "arm_group_label": "GAD-Alum (Diamyd) 20 \u00b5g x 2 and Vitamin D", 
                "arm_group_type": "Active Comparator", 
                "description": "GAD-Alum (Diamyd) 20 \u00b5g X 2 given twice with one month interval\nVitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study is to\n\n        -  evaluate the safety and influence of treatment with GAD-Alum (Diamyd) combined with\n           Vitamin D and Ibuprofen on preservation of residual insulin secretion in recently\n           diagnosed Type 1 Diabetes\n\n        -  evaluate how the above mentioned treatments influence the immune system of the subjects\n           and interact with any viral infections\n\n        -  evaluate the safety and influence of treatment with double dose of GAD-Alum (Diamyd)\n           plus Vitamin D on the immune system, viral infections, and on preservation of residual\n           insulin secretion in recently diagnosed Type 1 Diabetes"
        }, 
        "brief_title": "DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 1", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Male and female patients between 10 and 18 years of age\n\n          -  Insulin dependent Type 1 Diabetes mellitus diagnosed within the previous 4 months at\n             time of screening\n\n          -  Fasting C-peptide level at time of screening above or equal to 0.12 nmol/L\n\n          -  Elevated GAD65 antibodies (GADA) at time of screening\n\n        Main Exclusion Criteria:\n\n          -  Treatment with immunosuppressants, continuous anti-inflammatory drug, Vitamin D or\n             any anti-diabetic medications other than insulin\n\n          -  A history of certain diseases or conditions (e.g. anemia, HIV, epilepsy, head trauma,\n             neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)\n\n          -  Treatment with any vaccine within 4 months prior to first planned administration of\n             GAD-Alum/placebo or planned treatment with vaccine up to 4 months after the last\n             injections with GAD-Alum/Placebo, including influenza vaccines\n\n          -  Participation in other clinical trials with a new chemical entity within the previous\n             3 months\n\n          -  Pregnancy or planned pregnancy within 1 year after the last GAD-Alum/placebo  dose\n\n          -  Presence of associated serious disease or condition which in the opinion of the\n             investigator makes the patient non-eligible for the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785108", 
            "org_study_id": "DIABGAD-1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "GAD-Alum (Diamyd) 20\u00b5g, Vitamin D and Ibuprofen", 
                    "GAD-Alum (Diamyd) 20\u00b5g and Vitamin D"
                ], 
                "intervention_name": "GAD-Alum (Diamyd) 20 \u00b5g", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "GAD-Alum (Diamyd) 20 \u00b5g x 2 and Vitamin D", 
                "intervention_name": "GAD-Alum (Diamyd) 20 \u00b5g X 2", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "GAD-Alum (Diamyd) 20\u00b5g, Vitamin D and Ibuprofen", 
                    "GAD-Alum (Diamyd) 20\u00b5g and Vitamin D", 
                    "GAD-Alum (Diamyd) 20 \u00b5g x 2 and Vitamin D"
                ], 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "GAD-Alum (Diamyd) 20\u00b5g, Vitamin D and Ibuprofen", 
                "intervention_name": "Ibuprofen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins", 
                "Insulin", 
                "Ibuprofen", 
                "Aluminum sulfate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diamyd", 
            "Diabetes", 
            "Juvenile Diabetes", 
            "Diabetes type 1", 
            "Autoimmune Diabetes", 
            "Insulin dependent Diabetes", 
            "Type 1 diabetes", 
            "Type 1 diabetes mellitus", 
            "rhGAD65", 
            "GAD", 
            "GAD65", 
            "GAD-alum", 
            "Diabetes Mellitus", 
            "Diabetes Mellitus, Type 1", 
            "Glucose Metabolism Disorders", 
            "Metabolic Diseases", 
            "Vitamin D", 
            "Ibuprofen"
        ], 
        "lastchanged_date": "September 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Halmstad", 
                        "country": "Sweden", 
                        "zip": "SE-301 85"
                    }, 
                    "name": "Halmstad Hospital"
                }, 
                "investigator": {
                    "last_name": "Torben Ek", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huddinge", 
                        "country": "Sweden", 
                        "zip": "SE-141 86"
                    }, 
                    "name": "Astrid Lindgren Children's Hospital - Huddinge"
                }, 
                "investigator": {
                    "last_name": "Torun Torbjornsdotter, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kalmar", 
                        "country": "Sweden", 
                        "zip": "SE-391 85"
                    }, 
                    "name": "Kalmar Hospital"
                }, 
                "investigator": {
                    "last_name": "G\u00f6ran Lundstr\u00f6m, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Link\u00f6ping", 
                        "country": "Sweden", 
                        "zip": "SE-581 85"
                    }, 
                    "name": "Link\u00f6ping University"
                }, 
                "investigator": {
                    "last_name": "Johnny Ludvigsson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "zip": "SE-221 85"
                    }, 
                    "name": "Lund University Hospital"
                }, 
                "investigator": {
                    "last_name": "Annelie Carlsson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malm\u00f6", 
                        "country": "Sweden", 
                        "zip": "SE-205 02"
                    }, 
                    "name": "Sk\u00e5ne University Hospital, UMAS"
                }, 
                "investigator": {
                    "last_name": "Helena Larsson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "SE-171 76"
                    }, 
                    "name": "Astrid Lindgren Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Eva \u00d6rtqvist, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "SE-118 83"
                    }, 
                    "name": "Sachsska, S\u00f6dersjukhuset"
                }, 
                "investigator": {
                    "last_name": "Bj\u00f6rn Rathsman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uddevalla", 
                        "country": "Sweden", 
                        "zip": "SE-451 80"
                    }, 
                    "name": "Uddevalla Hospital"
                }, 
                "investigator": {
                    "last_name": "Ragnar Han\u00e5s, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u00d6rebro", 
                        "country": "Sweden", 
                        "zip": "SE-701 85"
                    }, 
                    "name": "\u00d6rebro University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jan \u00c5man, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "4", 
        "official_title": "Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen", 
        "overall_contact": {
            "email": "johnny.ludvigsson@liu.se", 
            "last_name": "Johnny Ludvigsson"
        }, 
        "overall_contact_backup": {
            "email": "rosaura.casas@liu.se", 
            "last_name": "Rosaura Casas"
        }, 
        "overall_official": {
            "affiliation": "Link\u00f6ping University", 
            "last_name": "Johnny Ludvigsson, MD,PhD,Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in C-peptide (90 minute value and AUC mean 0-120 min) during a Mixed Meal Tolerance Test from baseline to month 6, 15 and 30", 
            "safety_issue": "No", 
            "time_frame": "6 months, 15 months and 30 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785108"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Linkoeping University", 
            "investigator_full_name": "Johnny Ludvigsson", 
            "investigator_title": "MD, PhD, Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients with a stimulated maximum C-peptide level above 0.2 nmol/L", 
                "safety_issue": "No", 
                "time_frame": "6, 15 and 30 months"
            }, 
            {
                "measure": "Hemoglobin A1c (HbA1c), change between baseline and subsequent visits", 
                "safety_issue": "No", 
                "time_frame": "6, 15 and 30 months"
            }, 
            {
                "measure": "Exogenous insulin dose per kg body weight and 24  hours, change between baseline and subsequent visits", 
                "safety_issue": "No", 
                "time_frame": "6, 15 and 30 months"
            }, 
            {
                "measure": "Th2-deviation of cell-mediated immune response seen, e.g. as increased ratio of IL-5, 10, 13 in comparison with IFN-gamma, TNF-alfa, IL-1 beta, IL-17, and increase of T-regulatory cells", 
                "safety_issue": "No", 
                "time_frame": "6, 15 and 30 months"
            }, 
            {
                "measure": "Decrease in inflammatory markers, e.g. TNF-alfa, IL-1 beta, IL-2, IL-17", 
                "safety_issue": "No", 
                "time_frame": "6, 15 and 30 months"
            }, 
            {
                "measure": "Fasting C-peptide, change between baseline and month 6, 15 and 30", 
                "safety_issue": "No", 
                "time_frame": "6, 15 and 30 months"
            }
        ], 
        "source": "Linkoeping University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Swedish Child Diabetes Foundation (Barndiabetesfonden)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Research Council of South East Sweden (FORSS)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "ALF", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Diamyd Therapeutics AB (unrestricted grant)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Johnny Ludvigsson", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}